Form 4: 89bio Executive Sells Shares Under Pre-Arranged Trading Plan

An 89bio executive, Quoc Le-Nguyen, sold 10,963 shares of common stock at an average price of $6.49 per share, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Quoc Le-Nguyen, Chief Technical Operations Officer at 89bio, Inc., sold 10,963 shares of common stock on January 15, 2025.
• The shares were sold at a weighted average price of $6.49 per share.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on July 1, 2024.
• The sale price ranged from $6.36 to $6.60 per share.
• Following the transaction, Mr. Le-Nguyen directly owns 271,833 shares of 89bio stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan, with no indication of positive or negative sentiment.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, potentially impacting investor sentiment.

Industry Context

Executive stock sales are a common occurrence, and this transaction appears to be part of a pre-planned strategy under Rule 10b5-1, which is designed to avoid accusations of insider trading.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a standard practice among public company executives to manage their personal finances and avoid potential insider trading issues.
• The sale of 10,963 shares is not unusual for an executive of a company of 89bio's size.
• Comparable companies in the biotech sector often see similar transactions by their executives.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but the pre-planned nature of the sale mitigates this risk.

Key Dates

Keywords

89bio, insider trading, stock sale, Rule 10b5-1, executive, ETNB, Quoc Le-Nguyen